Article Text

Download PDFPDF

Amphotericin B lipid complex for neonatal invasive candidiasis
  1. F Adler-Shoheta,
  2. H Waskinb,
  3. J M Liebermana
  1. aMiller Children's Hospital, Long Beach, California and University of California, Irvine, California, USA, bThe Liposome Company, Princeton, New Jersey, USA
  1. Dr Lieberman, Pediatric Infectious Diseases, Miller Children's Hospital, 2801 Atlantic Ave, PO Box 1428, Long Beach, CA 90801–1428, USAjmlieberman{at}


This study describes the safety and efficacy of amphotericin B lipid complex (ABLC) in 11 neonates with systemicCandida infections. Nine of the 11 improved clinically, and eight of nine evaluable patients had a mycological cure with ABLC. Creatinine levels improved or did not significantly change in eight of the 11 patients.

  • Candida
  • neonate
  • amphotericin B lipid complex
View Full Text

Statistics from


    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.